Sensus Healthcare received approval from Health Canada for its non-surgical treatment for skin cancer. This recent approval follows similar ones by the FDA in the United States and the MHRA in the United Kingdom. The device has also received CE Mark approval in Europe. The device is called the SRT-100 and is intended as a skin cancer therapy device for use in private practices and shared healthcare facilities.

The SRT-100 skin cancer treatment system uses Sensus Healthcare’s proprietary SharpBeam technology. This technology facilitates the treatment of lesions with targeted radiation. This process minimizes damage to healthy tissue surrounding the skin cancer site. The device is designed for the treatment of non-melanoma skin cancer and provides a painless experience for patients.

In prepared remarks, CEO and president Joe Sardano said, "We consider Canada as one of the foremost authorities in providing cost effective technologies and we are delighted to have the SRT-100 considered as a viable choice.” He continued, "We are looking forward to working with Canada's healthcare professionals."

Sensus Health is based in Boca Raton, Florida. The company manufactures devices that use mobile x-ray technology for the treatment of non-melanoma cancers. According to statements by the company, the SRT-100 system is a more cost-effective solution for both healthcare providers and patients undergoing treatment for non-melanoma skin cancer.

References

www.sensushealthcare.com/news/news-27.php